The ethics of placebo research have been of paramount concern since the discovery of the phenomenon. To address these ethical concerns, Miller and colleagues (PLoS Med 2005 Sep;2(9):e262, 0853-0859) propose an alternate approach to placebo research, called ''authorized deception", in which participants are alerted of the use of deception in the research prior to study enrollment and thus knowingly permit its use if they decide to participate. The present study sought to investigate the authorized deception methodology in experimentally induced placebo analgesia. The participants were randomly assigned to an authorized deception or non-authorized deception group. A commonly used protocol was employed wherein heat pain stimulation was surreptitiously lowered following the application of a placebo cream during a series of conditioning trials and the magnitude of the placebo effect was subsequently assessed in test trials for which the stimulus intensity was the same for both the placebo and control creams. Authorized deception did not have any negative impact on the magnitude of the placebo effect, recruitment and retention of participants, nor did it result in any significant psychological harm. The majority of participants who received this form of consent preferred it to the traditional approach in which the participants are not alerted to the presence of deception. These findings suggest that the use of authorized deception is a viable and ethically preferable alternative consent process for laboratory-based studies on placebo analgesia. Further studies are needed to examine the effect of authorized deception in clinical trials and other placebo research within a clinical setting. Ó
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Introduction
Placebos have the potential to enhance the therapeutic outcome of medical interventions and are a source of important variability to be considered in clinical trials designed to evaluate treatment efficacy [14] . However, the methodology by which placebo effects are investigated has raised some ethical concerns [5,10,14,15]. Because placebo analgesia is strongly influenced by the recipient's expectations [16] [17] [18] , clinical and experimental studies typically rely on the use of deception regarding the purpose of the research and/or the nature of the treatment being administered, thereby leading the participants to believe that they are receiving a physically active treatment when in fact they are receiving a placebo [14] . This use of deception is often justified on the grounds that full disclosure about the purpose of the research or the experimental procedures may influence the participants' responses and thus jeopardize scientific knowledge [14] . As such, deception is often seen as a necessary means of promoting the internal and external validities of placebo research [13] .
However, as Miller and colleagues [13, 15] highlight, use of deception conflicts with ethical principles of human experimentation as it: (1) violates the principle of respect for persons by failing to disclose relevant information that might affect an individual's decision to volunteer for a research study; (2) may manipulate individuals to participate in research that they would not have; and (3) may cause distress and lack of trust in research when the deception is revealed. Furthermore, the American Pain Society position statement on the use of placebos in clinical pain management highlights, ''deception of patients about clinical treatments violates the right of patients to consent to or refuse treatment" ([22] p. 216).
Miller and colleagues [14, 15, 26] advocate an alternate approach to the consent process in deceptive research. The participants are informed, prior to deciding whether to participate in a study that some features of the study will or may be misleading or deceptive. They call this form of consent ''authorized deception", since the participants are alerted to the presence of deception in the research and thus knowingly permit its use if they decide to participate [15] . Additionally, the participants may be offered the opportunity to withdraw their data after they have been informed about the true nature of the study as a means of restoring participant autonomy [14] .
